Aadi Bioscience

FYARRO

Manufacturer:

Aadi Bioscience

Fyarro HCPCS:

J9331

HCPCS Code Descriptor:

Injection, sirolimus protein-bound particles, 1 mg

Category:

J Code

Fyarro NDCs:

80803-0153-50

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Fyarro:

FYARRO is an Oncology drug manufactured by Aadi Bioscience and administered via the Intravenous route of administration. The J Code: J9331 is aligned to the drug FYARRO.

Fyarro is a medication often prescribed for patients with malignant perivascular epithelioid cell tumors, also known as PEComa. Fyarro is given to patients whose tumors have spread to other parts of the body, or whose tumors cannot be surgically operated on. Fyarro is what's known as a targeted cancer treatment. It is thought to work by blocking one of the signals in cancer cells that cause them to grow out of control, thus stopping the growth and spread of the tumor.

ACCESS PRICING AND MORE BY REGISTERING

J9331 Added Date:

July 1, 2022

J9331 Effective Date:

July 1, 2022

J9331 Termination Date:

HCPCS Active

Fyarro billing and coding information can be found through Aadi Bioscience at the link below:
Fyarro patient assistance information can be found through Aadi Biosciences’ Aadi Assist Program at the URL: http://aadiassist.com/
FYARRO prescribing information can be found at the link below:
Information regarding FYARRO’s side effects can be found at MedlinePlus